Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

<ul>
<li>Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.</li>
<li>We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.</li>
<li>We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.</li>
</ul>


Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.
We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.
We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.


Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Insight Lifetech / Equity Capital Markets

<p>On August 18, 2021, <a href="https://www.smartkarma.com/entities/insight-lifetech-co-ltd" target="_blank" data-smartkarma-citation="entities:34278:1" rel="noopener">Insight Lifetech (ILT HK)</a> submitted its prospectus to the Hong Kong Stock Exchange and officially started its IPO process. Lifetech is a medtech company dedicated to developing precision solutions with the potential to transform the diagnosis and treatment of cardiovascular diseases. Founded more than five years ago, Lifetech had already gone through six rounds of financing (at least one round every year). This article mainly analyzed the industry characteristics, the business and the concerns of the Company.</p>

On August 18, 2021, Insight Lifetech (ILT HK) submitted its prospectus to the Hong Kong Stock Exchange and officially started its IPO process. Lifetech is a medtech company dedicated to developing precision solutions with the potential to transform the diagnosis and treatment of cardiovascular diseases. Founded more than five years ago, Lifetech had already gone through six rounds of financing (at least one round every year). This article mainly analyzed the industry characteristics, the business and the concerns of the Company.

Pre-IPO Insight Lifetech - Insights on Industry, Products and Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Insight Lifetech (ILT HK)

Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

Shanghai Pulse Medical is a leading player in the FFR assessment in China. We look at the product line of the company, including QFR, OFR and UFR.

Ke Yan, CFA, FRM

Pre-IPO Insight Lifetech - Insights on Industry, Products and Concerns

This article analyzed Insight Lifetech in terms of the industry characteristics of interventional cardiovascular devices, the products/candidates...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)